Ask clear questions before prp for back pain

PRP may help soreness, but the result is not certain

PRP means platelet-rich plasma, a prepared part of your own blood. Concentrated PRP is another form you may hear about. For back soreness, the small studies do not give one clear answer.

What is shown? Some people report less soreness after care. What is only suggested? The result may depend on the exact source and the product used. Rebuilding a worn disc remains unknown.

Ask which part of the back is thought to hurt and how that was decided. Then ask what change you might notice, how long it may take, and what the visit may cost. Don’t accept a scan picture as a promised outcome.

A sound choice includes risks and the next step

Every procedure has burdens as well as possible gains. You need to know about soreness after care, time away from normal tasks, and signs that need a call. Ask who handles a problem after hours.

A good plan also covers a weak result. You may return to guided movement, seek another view of the cause, or discuss other care. Surgery can still be right when a clear problem and your symptoms line up.

Until the appointment, avoid testing your back with a heavy lift on a better day. Keep notes on walking, sleep, and leg symptoms instead. QC Kinetix medical providers discuss regenerative treatments and orthobiologics for back soreness, including whether the choice fits your needs.

Sources

1. A 2026 double-blind randomised superiority trial of 76 patients with facet joint syndrome found PRP was NOT superior to corticosteroid: at six months only 6 PRP patients and 5 corticosteroid patients had reached the 50% pain-improvement endpoint, and there were no statistically significant differences in pain at 3, 6 or 12 months. The authors conclude the results 'do not support the use of PRP injections for facet joint syndrome.'

   Geoffroy M, Beissat M, Kanagaratnam L, Ackah Miezan S, Salmon JH — Platelet-rich plasma versus corticosteroids in facet joint syndrome: A controlled, randomized, double-blind study.. Joint Bone Spine, 2026. DOI: 10.1016/j.jbspin.2025.106001.

2. A double-blinded randomised trial at two university spine centres, using stringent inclusion criteria (>80% relief on a diagnostic block) and fluoroscopic guidance, compared sacroiliac joint PRP with sacroiliac steroid in 26 patients. Both groups improved, but the STEROID group reported lower pain and had significantly more responders (>=50% improvement) at one and three months than the PRP group. This is the best-designed sacroiliac comparison available and it favours the cheap conventional option.

   Chen AS, Solberg J, Smith C, et al. — Intra-Articular Platelet Rich Plasma vs Corticosteroid Injections for Sacroiliac Joint Pain: A Double-Blinded, Randomized Clinical Trial.. Pain Medicine, 2022. DOI: 10.1093/pm/pnab332.

3. The Mint trials randomised 681 patients with chronic low back pain and a POSITIVE diagnostic block - facet, sacroiliac, or a combination - to radiofrequency denervation plus a standardised exercise programme or the exercise programme alone. The prespecified minimal clinically important difference was 2 points. The actual differences at three months were 0.18, 0.71 and 0.99 points. The authors conclude the findings 'do not support the use of radiofrequency denervation to treat chronic low back pain from these sources.'

   Juch JNS, Maas ET, Ostelo RWJG, et al. — Effect of Radiofrequency Denervation on Pain Intensity Among Patients With Chronic Low Back Pain: The Mint Randomized Clinical Trials.. JAMA, 2017. DOI: 10.1001/jama.2017.7918.

4. The 2023 Cochrane review of spinal cord stimulation for low back pain included 13 studies and 699 participants and found NO study evaluated pain at 12 months or beyond. At six months, moderate-certainty evidence from the single available placebo-controlled trial showed SCS probably does not improve back or leg pain, function or quality of life versus placebo. In one study 13 of 42 people (31%) required revision surgery within 24 months. The authors state the data 'do not support the use of SCS to manage low back pain outside a clinical trial.'

   Traeger AC, Gilbert SE, Harris IA, Maher CG — Spinal cord stimulation for low back pain.. Cochrane Database of Systematic Reviews, 2023. DOI: 10.1002/14651858.CD014789.pub2.

5. The FDA states verbatim that stem cell products, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products have NOT been 'approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' No stem cell product is approved in the United States for any orthopedic use: the only ones with FDA approval at all are blood-forming cells derived from umbilical cord blood, approved solely for disorders of blood production, and there are currently no FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA.gov, 2025.

6. In January 2025 federal district court orders permanently banned the co-founders of the Stem Cell Institute of America and several related companies from marketing stem cell therapy, and required payment of $5,155,146 in civil penalties and consumer refunds. On summary judgment the court found the defendants had published false and misleading advertisements about the efficacy and approval of stem cell injections for a range of conditions. Their clinic charged up to $5,000 per injection, almost exclusively to elderly and disabled consumers.

   Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties.. FTC.gov, 2025.

7. A survey of internet-based marketing claims documented that direct-to-consumer promotion of unapproved stem cell interventions - long assumed to be a feature of countries with lax regulation - is widespread among businesses based in the United States, and concluded that regulatory agencies must better oversee this marketplace.

   Turner L, Knoepfler P — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.